Portfolio Holdings Detail for ISIN IE00B3VWM098

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE

Holdings detail for ARCT

Show aggregate ARCT holdings

News associated with ARCT

Arcturus Therapeutics (NASDAQ:ARCT) Given New $54.00 Price Target at Leerink Partners

Arcturus Therapeutics (NASDAQ:ARCT – Free Report) had its price target cut by Leerink Partners from $63.00 to $54.00 in a report released on Friday,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock. ARCT has been the subject of a number of other reports. Canaccord Genuity Group decreased their target price on […] - 2025-08-25 02:12:53

Mitsubishi UFJ Asset Management Co. Ltd. Grows Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 9.2% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,693 shares of the biotechnology company’s stock after buying an additional 1,232 shares during […] - 2025-08-15 04:46:53

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Rating of “Buy” from Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) have received an average rating of “Buy” from the seven analysts that are currently covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued ratings on the stock […] - 2025-08-12 04:42:57

Empire Life Investments Inc. Sells 14,554 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Empire Life Investments Inc. trimmed its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 5.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 264,909 shares of the biotechnology company’s stock after selling 14,554 shares during the period. […] - 2025-08-04 04:44:57

Alps Advisors Inc. Trims Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Alps Advisors Inc. reduced its holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 8.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,949 shares of the biotechnology company’s stock after selling 1,952 shares during the quarter. Alps Advisors Inc. owned approximately […] - 2025-07-18 04:49:09

Sumitomo Mitsui Trust Group Inc. Reduces Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Sumitomo Mitsui Trust Group Inc. reduced its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 6.7% in the first quarter, HoldingsChannel.com reports. The firm owned 1,926,084 shares of the biotechnology company’s stock after selling 138,966 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.07% of Arcturus Therapeutics […] - 2025-07-04 05:12:59

Arcturus Therapeutics (NASDAQ:ARCT) Stock Crosses Below 200 Day Moving Average – Time to Sell?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report)’s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $14.13 and traded as low as $13.74. Arcturus Therapeutics shares last traded at $14.41, with a volume of 517,333 shares changing hands. Wall Street Analyst […] - 2025-06-27 05:22:55

Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Scotiabank

Scotiabank began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a report released on Wednesday, Marketbeat Ratings reports. The brokerage set a “sector outperform” rating and a $32.00 price target on the biotechnology company’s stock. Scotiabank’s price objective would suggest a potential upside of 151.37% from the company’s previous close. A […] - 2025-05-30 02:38:46

Cresset Asset Management LLC Sells 2,198 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Cresset Asset Management LLC decreased its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 16.0% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 11,511 shares of the biotechnology company’s stock after selling 2,198 shares during the period. Cresset Asset Management LLC’s holdings in […] - 2025-05-19 05:02:55

Arcturus Therapeutics (NASDAQ:ARCT) Given New $66.00 Price Target at Canaccord Genuity Group

Arcturus Therapeutics (NASDAQ:ARCT – Free Report) had its target price reduced by Canaccord Genuity Group from $68.00 to $66.00 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. ARCT has been the topic of a number of other research reports. HC Wainwright […] - 2025-05-14 04:58:54

Hsbc Holdings PLC Increases Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Hsbc Holdings PLC grew its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 11.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,368 shares of the biotechnology company’s stock after acquiring an additional 2,673 shares during the […] - 2025-05-08 06:07:00

Barclays PLC Lowers Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Barclays PLC trimmed its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 10.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 60,082 shares of the biotechnology company’s stock after selling 7,333 shares during the period. Barclays PLC’s holdings in Arcturus Therapeutics were worth $1,020,000 as of its most […] - 2025-05-06 04:38:59

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Holdings Lessened by Franklin Resources Inc.

Franklin Resources Inc. lessened its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 3.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 100,677 shares of the biotechnology company’s stock after selling 3,259 shares during the period. […] - 2025-04-15 05:32:54

Mitsubishi UFJ Asset Management Co. Ltd. Purchases 4,647 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 52.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,461 shares of the biotechnology company’s stock after acquiring an additional 4,647 […] - 2025-04-04 05:12:56

AlphaQuest LLC Sells 12,668 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

AlphaQuest LLC cut its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 63.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,142 shares of the biotechnology company’s stock after selling 12,668 shares during the period. AlphaQuest LLC’s holdings in […] - 2025-03-19 06:06:45

Arcturus Therapeutics (NASDAQ:ARCT) Given New $68.00 Price Target at Canaccord Genuity Group

Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) had its price objective reduced by stock analysts at Canaccord Genuity Group from $74.00 to $68.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 414.76% […] - 2025-03-12 04:08:56

Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below 200-Day Moving Average – Here’s Why

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $18.81 and traded as low as $16.51. Arcturus Therapeutics shares last traded at $16.69, with a volume of 364,852 shares. Wall Street Analysts Forecast Growth Several research […] - 2025-02-25 06:50:59

Spire Wealth Management Increases Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Spire Wealth Management increased its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Free Report) by 393.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,478 shares of the biotechnology company’s stock after buying an additional 10,746 shares during the […] - 2025-02-07 07:05:06

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc ARCT holdings

Share Trades of ARCT by Blackrock for IE00B3VWM098

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-06-02	SELL	-3,085	12.810	13.600	13.521	USD -41,712	15.03 Profit of 4,661 on sale
2025-05-30	SELL	-12,970	12.530	12.830	12.800	USD -166,016	15.05 Profit of 29,184 on sale
2025-05-23	BUY	55	12.200	12.800	12.740	USD 701	15.16
2025-05-19	SELL	-55	11.990	12.330	12.296	USD -676	15.25 Profit of 162 on sale
2025-05-15	SELL	-165	11.640	11.640	11.640	USD -1,921	15.30 Profit of 604 on sale
2025-05-12	SELL	-55	11.590	12.220	12.157	USD -669	15.40 Profit of 178 on sale
2025-05-09	SELL	-55	10.980	11.740	11.664	USD -642	15.43 Profit of 207 on sale
2025-04-30	SELL	-55	12.810	12.870	12.864	USD -708	15.65 Profit of 153 on sale
2025-04-24	SELL	-110	12.890	12.940	12.935	USD -1,423	15.75 Profit of 310 on sale
2025-04-17	SELL	-55	10.530	10.660	10.647	USD -586	15.96 Profit of 292 on sale
2025-04-15	SELL	-165	10.570	11.000	10.957	USD -1,808	16.07 Profit of 843 on sale
2025-04-14	SELL	-165	10.180	10.330	10.315	USD -1,702	16.12 Profit of 958 on sale
2025-04-09	SELL	-220	9.820	10.380	10.324	USD -2,271	16.32 Profit of 1,319 on sale
2025-04-07	SELL	-385	9.090	9.130	9.126	USD -3,514	16.47 Profit of 2,828 on sale
2025-04-04	SELL	-550	9.110	9.350	9.326	USD -5,129	16.55 Profit of 3,972 on sale
2025-03-31	BUY	55	10.590	11.240	11.175	USD 615	16.76
2025-03-19	SELL	-110	13.400	13.880	13.832	USD -1,522	17.15 Profit of 365 on sale
2025-03-14	SELL	-330	14.080	14.290	14.269	USD -4,709	17.27 Profit of 989 on sale
2025-03-13	SELL	-110	13.900	14.560	14.494	USD -1,594	17.31 Profit of 309 on sale
2025-03-12	SELL	-1,870	14.260	14.500	14.476	USD -27,070	17.35 Profit of 5,366 on sale
2025-03-07	SELL	-110	14.550	15.400	15.315	USD -1,685	17.47 Profit of 238 on sale
2025-03-06	SELL	-165	15.970	16.180	16.159	USD -2,666	17.49 Profit of 220 on sale
2025-03-03	SELL	-55	15.680	17.320	17.156	USD -944	17.57 Profit of 23 on sale
2025-02-28	SELL	-7,745	16.790	16.900	16.889	USD -130,805	17.58 Profit of 5,334 on sale
2025-02-26	SELL	-75	16.580	17.060	17.012	USD -1,276	17.61 Profit of 45 on sale
2025-02-25	SELL	-225	16.060	16.940	16.852	USD -3,792	17.64 Profit of 176 on sale
2025-02-18	BUY	375	17.710	19.250	19.096	USD 7,161	17.66
2025-02-13	BUY	75	16.410	16.460	16.455	USD 1,234	17.67
2025-02-12	BUY	75	15.860	16.400	16.346	USD 1,226	17.70
2025-02-11	BUY	225	16.070	16.250	16.232	USD 3,652	17.73
2025-02-06	BUY	675	17.290	18.050	17.974	USD 12,132	17.79
2025-01-27	BUY	75	16.490	17.740	17.615	USD 1,321	17.97
2025-01-22	SELL	-150	16.740	17.930	17.811	USD -2,672	18.03 Profit of 33 on sale
2025-01-17	SELL	-75	16.790	17.510	17.438	USD -1,308	18.13 Profit of 52 on sale
2025-01-16	BUY	75	17.010	17.060	17.055	USD 1,279	18.15
2025-01-14	BUY	225	16.590	17.670	17.562	USD 3,951	18.23
2025-01-13	BUY	150	17.310	17.730	17.688	USD 2,653	18.25
2025-01-08	BUY	450	18.950	20.940	20.741	USD 9,333	18.22
2024-12-30	BUY	375	16.580	16.910	16.877	USD 6,329	18.31
2024-12-06	BUY	300	19.090	20.920	20.737	USD 6,221	18.26
2024-12-05	BUY	75	17.850	17.920	17.913	USD 1,343	18.28
2024-12-04	BUY	375	17.220	18.310	18.201	USD 6,825	18.31
2024-11-29	BUY	375	18.340	18.610	18.583	USD 6,969	18.32
2024-11-27	BUY	300	17.510	17.720	17.699	USD 5,310	18.39
2024-11-26	BUY	75	16.930	17.830	17.740	USD 1,330	18.45
2024-11-21	BUY	375	17.070	17.300	17.277	USD 6,479	18.65
2024-11-20	BUY	225	16.170	17.940	17.763	USD 3,997	18.79
2024-11-18	BUY	900	16.270	17.370	17.260	USD 15,534	18.99
2024-11-12	BUY	600	19.580	20.070	20.021	USD 12,013	18.95
2024-11-08	BUY	375	19.630	19.930	19.900	USD 7,463	18.91
2024-11-07	BUY	1,125	18.740	19.280	19.226	USD 21,629	18.92
2024-11-06	BUY	150	18.330	19.300	19.203	USD 2,880	18.97
2024-10-31	BUY	75	17.730	18.350	18.288	USD 1,372	19.46

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ARCT

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy